Bimagrumab (BYM338): dosing
> Updated:
Calculate the Bimagrumab (BYM338) dose
Enter your dose and diluent volume for Bimagrumab (BYM338) — the calculator will do the rest.
Human dosing
Bimagrumab (BYM338) dosing is always tied to an intravenous infusion at a clinical site on a fixed visit schedule every 4 weeks, unlike subcutaneous peptides that a person injects themselves; that structure is what shapes the schedule below.
| Period / condition | Dose | Escalation |
|---|---|---|
| Early studies (phase I) | 210–700 mg IV every 4 weeks | Starting dose |
| Main phase II regimen | 10 mg/kg (max 1200 mg) IV every 4 weeks | Increase if needed |
| Later studies | 10–30 mg/kg IV every 12 weeks | Maximum in this schedule |
Practical dosage and effect notes
In a trial by Heymsfield and colleagues (JAMA Network Open, 2021), adults with obesity and type 2 diabetes received bimagrumab on exactly the table's "Main phase II regimen": 10 mg/kg (max 1200 mg) intravenously every 4 weeks, 12 infusions over 48 weeks. Body fat mass fell by 20.5% on average (minus 7.49 kg) versus 0.5% with placebo, while lean mass rose 3.6% (plus 1.70 kg), against a 0.8% decline with placebo.
That is why bimagrumab's dose is scaled to body weight (mg/kg) rather than fixed as a flat number the way most peptides are: the same 10 mg/kg dose delivers a different milligram amount to a 60 kg person than a 100 kg one. The infrequent dosing, every 4–12 weeks, reflects the monoclonal antibody's long half-life, not a chosen interval.
This is background for planning a research protocol, not a medical recommendation and not instructions for self-administration.
How to reconstitute
An example reconstitution for convenient dosing. The exact ratios depend on your vial. For research reference only — not medical guidance.
- 1Add the diluentUse bacteriostatic water. Example: 2 ml into a 10 mg vial.Bimagrumab (BYM338)10 mg+ 2 mlDiluent
- 2Get the concentrationExample: 10 mg in 2 ml =Bimagrumab (BYM338)5 mg/ml(5,000 mcg/ml)
- 3Work out the volume per doseFor example, for a 2.5 mg dose:2.5 mg = 0.5 ml= 50 u. (U-100)
This is only an example calculation. You can use a different diluent volume — plug your own numbers into the calculator. Open calculator →
Research protocols
Bimagrumab: reference regimens
Bimagrumab (BYM338) is a monoclonal antibody that in clinical studies was given mainly by intravenous infusion.
More scientific background in the Bimagrumab (BYM338) monograph
Notes and safety
- • Bimagrumab (BYM338) is a research peptide. Human safety and efficacy data are limited.
- • The regimens shown are based on publications and research protocols, not clinical recommendations.
- • Individual reactions may vary. Published protocols typically start dosing at the lower end of the reported range.
- • Not recommended for use with chronic illness, pregnancy, or breastfeeding.
- • This information is for educational purposes and is not medical advice.
Bimagrumab (BYM338)